GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cochlear Ltd (ASX:COH) » Definitions » Cash And Cash Equivalents

Cochlear (ASX:COH) Cash And Cash Equivalents : A$485 Mil (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Cochlear Cash And Cash Equivalents?

Cochlear's quarterly cash and cash equivalents increased from Dec. 2022 (A$546.70 Mil) to Jun. 2023 (A$555.50 Mil) but then stayed the same from Jun. 2023 (A$555.50 Mil) to Dec. 2023 (A$485.20 Mil).

Cochlear's annual cash and cash equivalents increased from Jun. 2021 (A$609.60 Mil) to Jun. 2022 (A$629.30 Mil) but then declined from Jun. 2022 (A$629.30 Mil) to Jun. 2023 (A$555.50 Mil).


Cochlear Cash And Cash Equivalents Historical Data

The historical data trend for Cochlear's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cochlear Cash And Cash Equivalents Chart

Cochlear Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 78.60 565.00 609.60 629.30 555.50

Cochlear Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 553.10 629.30 546.70 555.50 485.20

Cochlear Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Cochlear  (ASX:COH) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Cochlear Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Cochlear's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Cochlear (ASX:COH) Business Description

Traded in Other Exchanges
Address
1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109
Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.

Cochlear (ASX:COH) Headlines

No Headlines